Trials / Completed
CompletedNCT02238223
Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet
Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Tablet
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,001 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Study to investigate the safety and efficacy information of Alesion® Tablet under the proper use in daily clinical practice after new treatment guideline for allergic rhinitis, bronchial asthma, eczema, dermatitis, urticaria, pruritus, prurigo and psoriasis vulgaris with itching
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alesion® |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2006-05-01
- First posted
- 2014-09-12
- Last updated
- 2014-09-12
Source: ClinicalTrials.gov record NCT02238223. Inclusion in this directory is not an endorsement.